Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on ...

The Californian company earlier announced positive data at 52 weeks in a double-blind, dose-ranging Phase II study with ...

BRL Medicine raised $27 million in a Series B+ round, led by CSPC Fund, to advance its gene and cell therapies for genetic ...

US central nervous system (CNS) disorders specialist Axsome Therapeutics (Nasdaq: AXSM) today released encouraging late-stage ...

Italian oncology focused biotech Nerviano Medical Sciences yesterday announced that it has successfully negotiated with ...

Roche’s Phase III SKYSCRAPER-01 trial missed its primary endpoint, with tiragolumab combined with Tecentriq failing to ...

Spanish HIV focused immunotherapies company AELIX Therapeutics, a spin-off of IrisCaixa, has announced the acquisition of its ...

Chinese gene therapy firm Kanglin Biotechnology has completed a $20 million series A financing round, with the money ...

All the news that moves the needle in pharma and biotech Exclusive features, podcasts, interviews, data analyses and ...

South African-Australian private equity firm LeapFrog Investments has announced the close of its fourth fund (Fund IV), with ...

Pyxis Oncology (Nasdaq: PYXS) has announced what look like encouraging early data from a Phase I trial of PYX-201, its lead ...

US biopharma Biohaven has provided an update regarding the taldefgrobep alfa development programs in spinal muscular atrophy ...